A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate‐resistant prostate cancer

Daniel J. George(Duke University), Andrew J. Armstrong(Duke University), Colleen Riggan(Duke University), Kellie Shobe(Duke University), Megan McNamara(Duke Medical Center), Jennifer A. Freedman(Duke Medical Center), Carol Winters(Duke University), Dadong Zhang(Precision for Medicine (United States)), Alexander B. Sibley(Duke University), Kouros Owzar(Duke University), Monika Anand(Duke University), Brendon M. Patierno(Duke University), Michael Goodman(Emory University), Julie J.G. Kephart(Duke University), Guru Sonpavde(AdventHealth Orlando), Susan Halabi(Duke Medical Center), Rhonda L. Bitting(Cancer Research Institute of the Slovak Academy of Sciences), Terry Hyslop(Thomas Jefferson University), Patrick Healy(Duke University), Steven R. Patierno(George Washington University), Devika Das(University of Mississippi Medical Center), Bonnie LaCroix(Duke University), Rhonda Wilder(Duke University), Oliver Sartor(Mayo Clinic), Julia Rasmussen(Duke University), Mark T. Fleming(Virginia Oncology Associates), Matthew I. Milowsky(UNC Lineberger Comprehensive Cancer Center), Rick A. Kittles(Morehouse School of Medicine), Tian Zhang(Duke Medical Center), William R. Berry(Duke University), Elisabeth I. Heath(The Barbara Ann Karmanos Cancer Institute), James D. Bearden(Spartanburg Regional Healthcare System), Michael R. Harrison(Pfizer (United States))
Cancer
May 5, 2021
Cited by 42


Related Papers